Date: February 11, 2026

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

Sub: Outcome of Board Meeting held on 11.02.2026

With reference to the subject cited, this is to inform the exchange that the Board of Directors of Jeevan Scientific Technology Limited at its meeting held on Wednesday, 11.02.2026 at 12:30 p.m. at the registered office of the Company, inter alia approved the following items of business:

1. Un-Audited Financial Results (Standalone and Consolidated) for the Quarter and nine months ended 31.12.2025. **(Attached)**

2. Limited Review Report (Standalone and Consolidated) for the Quarter and nine months ended 31.12.2025. **(Attached)**

The meeting concluded at 14:00 P.M.

This is for the information and records of the Exchange, please.

Thanking You.

Yours faithfully,
For Jeevan Scientific Technology Limited

KODATI KRISHNA SAI NADH
Digitally signed by KODATI KRISHNA SAI NADH
Date: 2026.02.11 14:05:00 +05'30'

Kodati Krishna Sainadh
Company Secretary & Compliance Officer

Encl as above

Jeevan Scientific Technology Limited
CIN:L72200TG1999PLC031016
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2025
(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenue from operations						
	(a) Net sales/Income from operations	1,690.66	1,043.17	1,186.64	3,555.40	3,468.50	4,360.99
I	**Total revenue from operation**	**1,690.66**	**1,043.17**	**1,186.64**	**3,555.40**	**3,468.50**	**4,360.99**
II	Other Income	18.06	26.30	21.62	82.15	48.82	62.92
III	**Total income (I+II)**	**1,708.72**	**1,069.47**	**1,208.26**	**3,637.55**	**3,517.32**	**4,423.90**
IV	**Expenses**						
	(a) Cost of materials consumed	138.17	93.77	80.96	294.21	252.92	365.10
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(c) Employee benefits expense	456.77	425.73	367.59	1303.98	1,103.84	1,565.30
	(d) Finance costs	38.17	38.12	25.74	112.37	68.19	103.56
	(e) Depreciation and Amortization expense	135.24	144.72	123.20	429.55	376.03	528.91
	(f) Other Expenses	630.80	376.55	534.08	1456.43	1,374.22	1,783.97
	Total Expenses (IV)	**1,399.15**	**1,078.89**	**1,131.57**	**3,596.54**	**3,175.20**	**4,346.86**
V	**Profit/ (Loss) before Tax (III-IV)**	**309.57**	**(9.42)**	**76.69**	**41.01**	**342.12**	**77.05**
VI	**Tax Expenses**						
	(a) Current tax	6.40	-	11.96	6.40	53.37	12.02
	(b) MAT Credit / (Entitlement)	(6.40)	-	(11.96)	(6.40)	(53.37)	(12.02)
	(c) Deferred tax	79.51	(0.88)	44.44	35.48	134.84	3.48
	Total tax expense	**79.51**	**(0.88)**	**44.44**	**35.48**	**134.84**	**3.48**
VII	**Profit(Loss) for the period/year (V-VI)**	**230.06**	**(8.54)**	**32.25**	**5.53**	**207.28**	**73.57**
VIII	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified subsequently to profit or loss	-	11.78	-	11.78	(3.83)	(1.37)
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss		-	-		-	-
	B (i) Items that will be reclassified subsequently to profit or loss		-	-		-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-		-	-
	Total other comprehensive income/(loss) for the period	**-**	**11.78**	**-**	**11.78**	**(3.83)**	**(1.37)**
IX	**Total Comprehensive income for the period (VII+VIII)**	**230.06**	**3.24**	**32.25**	**17.31**	**203.45**	**72.20**

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

R. Venkateswara Rao

X	Paid Up equity share capital (Face value of Rs.10/- each)	1,583.40	1,583.40	1,583.40	1,583.40	1,583.40	1,583.40
XI	Other equity					-	3,508.41
XII	Earnings per equity share (of Rs. 10/- each) (not annualized for the quarters)						
	a) Basic	1.45	(0.05)	0.21	0.03	1.33	0.47
	b) Diluted	1.45	(0.05)	0.20	0.03	1.30	0.46

Notes to the UnAudited financial results

1 The above Unaudited standalone financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.

2 The above Unaudited standalone results have been reviewed by the Audit Committee at its meeting held on 11th February, 2026 and approved by the Board of Directors of the Company at their meeting held on 11th February, 2026. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and issued unmodified conclusion.

3 Employee benefit expenses for the Quarter ending 31st December 2025 includes Rs.12.02 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".

4 The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.

5 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21,2025. The corresponding supporting rules under these codes are yet to be notified. The Company continues to monitor the finalisation of Central/State Rules and Clarifications from the Government on the other aspects of New Labour Code. The Company has estimated and accounted for incremental liability for employees, which is not material to the financial results.

6 The results for the Quarter and Nine Months ended 31st December 2025 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

R.Venkateswara Rao

Venkateswara Rao Ravipati
Chief Financial Officer

Place: Hyderabad.
Date: 11th February, 2026

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
CIN:L72200TG1999PLC031016
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2025
(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
	Revenue from operations						
	(a) Net sales/Income from operations	1,907.15	1,237.95	1,250.72	4,025.02	3,678.57	4,684.36
I	**Total revenue from operation**	**1,907.15**	**1,237.95**	**1,250.72**	**4,025.02**	**3,678.57**	**4,684.36**
II	Other Income	14.05	20.37	22.78	67.85	50.60	65.26
III	**Total income (I+II)**	**1,921.20**	**1,258.32**	**1,273.50**	**4,092.87**	**3,729.17**	**4,749.62**
IV	**Expenses**						
	(a) Cost of materials consumed	148.66	99.53	85.28	325.52	264.88	380.25
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(c) Employee benefits expense	555.00	510.36	403.41	1,567.13	1,206.72	1,705.71
	(d) Finance costs	54.27	54.96	43.32	163.13	121.49	176.09
	(e) Depreciation and Amortization expense	160.00	169.38	147.62	503.41	448.08	625.16
	(f) Other Expenses	680.66	421.00	554.71	1,580.98	1,427.64	1,857.34
	Total Expenses (IV)	**1,598.59**	**1,255.24**	**1,234.34**	**4,140.17**	**3,468.81**	**4,744.55**
V	**Profit/ (Loss) before tax (III-IV)**	**322.61**	**3.08**	**39.16**	**(47.30)**	**260.36**	**5.07**
VI	**Tax expenses**						
	(a) Current tax	6.40	-	11.96	6.40	53.37	12.02
	(b) MAT Credit / (Entitlement)	(6.40)	-	(11.96)	(6.40)	(53.37)	(12.02)
	(c) Deferred tax	82.52	2.10	34.60	33.56	128.24	(0.84)
VII	**Profit/(Loss) for the period/year**	**240.09**	**0.97**	**4.56**	**(80.86)**	**132.12**	**5.90**
VIII	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified subsequently to profit or loss	-	11.78	-	11.78	(3.83)	(1.37)
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-		-	-
	B (i) Items that will be reclassified subsequently to profit or loss	-	-	-		-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-		-	-
	Comprehensive Income for the period /year	-	**11.78**	-	**11.78**	**(3.83)**	**(1.37)**
IX	**Total Comprehensive Income for the period /year**	**240.09**	**12.75**	**4.56**	**(69.08)**	**128.29**	**4.53**
X	**Paid Up Equity Share Capital (Face Value of Rs.10/- each)**	**1,583.40**	**1,583.40**	**1,583.40**	**1,583.40**	**1,583.40**	**1,583.40**
XI	**Other equity excluding revaluation reserve**			-		-	**3,410.97**

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

R. Venkateswara Rao

XII	**Earnings per Equity share**						
	a) Basic (Amount in Rupees)	1.52	0.01	0.03	(0.51)	0.85	0.04
	b) Diluted (Amount in Rupees)	1.52	0.01	0.03	(0.51)	0.83	0.04
XIII	**Net profit attributable to:**						
	Owners of the company	142.28	(8.75)	10.50	(58.43)	143.34	13.43
	Non-Controlling interest	97.81	9.72	(5.94)	(22.43)	(11.22)	(7.53)
XIV	**Other comprehensive income attributable to:**						
	Owners of the company	0	11.78	-	11.78	(3.83)	(1.37)
	Non-Controlling interest		-	-		-	-
XV	**Total comprehensive income attributable to:**						
	Owners of the company	142.28	3.03	10.50	(46.65)	139.51	12.06
	Non-Controlling interest	97.81	9.72	(5.94)	(22.43)	(11.22)	(7.53)

Notes to the Un Audited financial results

1 The above UnAudited Consolidated financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.

2 The above UnAudited Consolidated results have been reviewed by the Audit Committee at its meeting held on 11th Februar, 2026 and approved by the Board of Directors of the Company at their meeting held on 11th Februar, 2026. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and issued unmodified conclusion.

3 Employee benefit expenses for the Quarter ending 31st December 2025 includes Rs.12.02 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".

4 The company operates in one reportable business segment i.e. Clinical Research Services. Hence segmental reporting as per Ind AS 108 is not applicable.

5 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21,2025. The corresponding supporting rules under these codes are yet to be notified. The Company continues to monitor the finalisation of Central/Slate Rules and Clarifications from the Government on the other aspects of New Labour Code. The Company has estimated and accounted for incremental liability for employees, which is not material to the financial results.

6 The results for the Quarter and Nine Months ended 31st December 2025 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

R.Venkateswara Rao

Venkateswara Rao Ravipati
Chief Financial Officer

Place: Hyderabad.
Date: 11th February, 2025

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed underSection 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement basedon our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity',issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial informationconsists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less inscope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not expressan audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pavuluri & Co
Chartered Accountants
FRN : 012194s

CA.N.Rajesh
Partner
M.No : 223169

Place : Hyderabad
Date :11/02/2026

UDIN # 26223169FOEXNC6901

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiary together referred to as "Group"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed underSection 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement basedon our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity',issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial informationconsists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less inscope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not expressan audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The consolidated unaudited financial results include the interim financial results of subsidiary company M/s Nayas Laboratories Private Limited. These unaudited financial results and other unaudited financial information have been furnished to us by the management and have been reviewed by us.

5. Based on our review conducted as stated in paragraph 3 above and based on the consideration of the review by us referred in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in termsof Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

6. We have reviewed the interim financial information of the subsidiary M/s Nayas Laboratories Private Limited included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs 194.18 lakhs for the quarter ended December 31, 2025 total net profit after tax of Rs 9.50 lakhs for the quarter ended December 31, 2025 and total comprehensive income of Rs 9.50 lakhs for the quarter ended December 31, 2025, as considered in the statement. This interim financial information has been reviewed by us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the review done by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

For Pavuluri & Co
Chartered Accountants
FRN : 012194s

CA.N.Rajesh
Partner
M.No : 223169

Place : Hyderabad
Date :11/02/2026

UDIN # 26223169TPHGPG1985